Table 1 Patient baseline characteristics
n = 30 | ||
|---|---|---|
Age [yrs] | 68 ± 8 | |
Gender | Male | 25 (83%) |
Cardiovascular risk factors | Hypertension | 24 (80%) |
Family history for CVD | 15 (50%) | |
Hyperlipidemia | 25 (83%) | |
Diabetes mellitus | 10 (33%) | |
Smoking | 2 (6.7%) | |
Symptoms | None | 3 (10%) |
Angina pectoris (AP) | 16 (53.3%) | |
Typical AP | 13 | |
CCS I | – | |
CCS II | 8 | |
CCS III | 5 | |
CCS IV | 3 | |
Atypical AP | 3 | |
Dyspnea | 6 (20%) | |
NYHA I | 1 | |
NYHA II | 4 | |
NYHA III | 1 | |
NYHA IV | – | |
Typ. AP + Dyspnea | 5 (16.7%) | |
Medication | ASS | 13 (43.3%) |
DAPT | 7 (23.3%) | |
ACE/ARB-Inhibitor | 13 (43.3%) | |
Betablockers | 13 (43.3%) | |
Statins | 17 (56.7%) | |
Nitrates/CCB | 13 (43.3%) | |
OAD | 6 (20%) | |
ECG abnormalities | 20 (66.7%) | |
Known CAD | 14 (46.7%) | |
Prior CABG | 4 (13.3%) | |
Prior MI/Myocardial scar | 9 (30%) | |
Caffeine levels [mg/L] | baseline CMR | < 1 |
follow-up CMR | 4.6 ± 2.2 | |
Daily caffeine consumption [cups] | coffee | 3.0 ± 1.9 |
tea | 3.0 ± 1.5 | |
Time between baseline and follow-up CMR [days] | 13.9 | |
CMR findings | ||
LV-EF [%] | 62.7 ± 8.4 | |
LV-EDV [ml] | 132.3 ± 33.2 | |
LV-ESV [ml] | 51.6 ± 24.0 | |
LA [cm2] | 21.6 ± 4.0 | |
IVS [mm] | 12.6 ± 2.4 |